Taken together, these findings suggest that activation of the PERK/EIF2A/ATF/CHOP pathway contributes to AAA development, and inhibition abrogates aneurysm formation by decreasing VSMC apoptosis. The gene discussed is EIF2A; the disease is triple-A syndrome.